Clarient Buys Applied Genomics to Pave Way to EGFR Testing Market for NSCLC | GenomeWeb

By Turna Ray

Vying to capture
what CEO Ron Andrews hopes will be Clarient's "unfair share" of the rapidly growing epidermal growth factor receptor testing market, the healthcare services provider announced plans to acquire Applied Genomics this week.

The all-stock merger, valued at up to $17.6 million, will make Applied Genomics a wholly-owned subsidiary of Clarient.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

BMJ study says that about half of former hematology-oncology regulators now work for industry.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.